2025-07-10 - Analysis Report
Okay, here's a comprehensive analysis of Recursion Pharmaceuticals Inc. (RXRX) based on the provided data, presented in English with concise numerical summaries and analysis:

## RXRX Stock Analysis

**Ticker:** RXRX
**Company Name:** Recursion Pharmaceuticals Inc.
**Description:** Recursion Pharmaceuticals is a clinical-stage biotechnology company leveraging AI and machine learning to discover and develop novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -47.82%
*   **VOO Cumulative Return:** 34.02%
*   **Divergence:**
    *   **Current:** -86.5
    *   **Max:** 35.8
    *   **Min:** -87.9
    *   **Relative Divergence:** 1.1

**Analysis:** RXRX has significantly underperformed the S&P 500 (VOO) over the covered period. The current divergence of -86.5 indicates substantial underperformance, placing it near the lowest end of its historical divergence range.

#### Alpha, Beta Analysis

| Year       | CAGR    | MDD     | Alpha   | Beta   | Cap(B) |
|------------|---------|---------|---------|--------|--------|
| 2021-2023  | 5.0%    | 73.6%   | -1.0%   | -0.1   | 4.0    |
| 2022-2024  | 0.0%    | 73.6%   | -25.0%  | 0.1    | 2.8    |
| 2023-2025  | 4.0%    | 73.6%   | -43.0%  | 0.1    | 2.3    |

**Analysis:**
*   **CAGR:** The Compound Annual Growth Rate (CAGR) has fluctuated, ranging from 0% to 5%, indicating inconsistent growth over different periods.
*   **MDD:** The Maximum Drawdown (MDD) is consistently high at 73.6%, highlighting significant risk and volatility in the stock's price.
*   **Alpha:** The consistently negative Alpha values (-1.0% to -43.0%) suggest that RXRX has underperformed relative to its benchmark (S&P 500) after adjusting for risk.
*   **Beta:** The Beta values close to 0 (ranging from -0.1 to 0.1) indicate that RXRX's price movements are not strongly correlated with the broader market. This could mean the stock is relatively insensitive to market trends or influenced by company-specific factors.
*   **Cap(B):** The market capitalization has decreased from $4.0B to $2.3B over the periods, indicating a decline in the company's market value.

### 2. Recent Price Action

*   **Current Price:** 5.6394
*   **Last Market Data:** `{'price': 5.6397, 'previousClose': 5.36, 'change': 5.22}` (Significant positive change)
*   **5-day Moving Average:** 5.2359
*   **20-day Moving Average:** 5.1585
*   **60-day Moving Average:** 4.9746

**Analysis:** The current price is above all three moving averages, suggesting a recent upward trend. The significant positive change in the last market data indicates a potentially strong upward momentum and could reflect recent news or events impacting investor sentiment.

### 3. Market Risk Indicators & Signals

*   **MRI (Market Risk Indicator):** 0.3373 (Low Risk)
*   **RSI (Relative Strength Index):** 60.45 (Approaching overbought territory)
*   **PPO (Percentage Price Oscillator):** 0.4363 (Positive, indicating bullish momentum)
*   **Hybrid Signal:** `cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)`
*   **Delta_Previous_Relative_Divergence (20-day):** -3.1 (Short-term decline in relative performance)
*   **Expected Return (%):** -2359.4 (Significantly negative long-term expected return vs. S&P 500)

**Analysis:** The MRI suggests low market risk. The RSI approaching 70 indicates that the stock might be nearing overbought conditions, potentially signaling a pullback. The PPO supports the recent upward momentum. However, the Hybrid Signal advises caution, even with a buy signal, likely due to the underlying risks. The negative change in relative divergence indicates weakening performance relative to the S&P 500, despite the recent price increase. The extremely negative expected return is a major red flag, suggesting very poor long-term prospects compared to the broader market.

### 4. Recent News & Significant Events

*   **2025-07-08:** Major business developments, regulatory changes, or market events.
*   **2025-07-10:** Analyst discussions regarding recent performance and outlook.
*   **2025-07-07:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-07-09:** Market experts highlight both risks and opportunities.

**Analysis:** The recent news suggests that RXRX is experiencing significant events influencing its stock price. Volatility and analyst discussions point to uncertainty and potential catalysts for price movements. Investors should closely monitor company announcements and news for further insights.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출       |
|------------|--------|------------|
| 2025-05-05 | -0.5   | 0.01 B$    |
| 2024-11-06 | -0.34  | 0.03 B$    |
| 2024-08-08 | -0.4   | 0.01 B$    |
| 2024-05-09 | -0.39  | 0.01 B$    |
| 2025-05-05 | -0.39  | 0.01 B$    |

**Analysis:** The company has consistently reported negative Earnings Per Share (EPS) and low revenue, indicating a lack of profitability. This is typical for clinical-stage biotech companies, but the continued losses should be carefully considered.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.01B  | -47.31%       |
| 2024-12-31 | $0.00B  | -183.62%      |
| 2024-09-30 | $0.03B  | 53.69%        |
| 2024-06-30 | $0.01B  | 36.14%        |
| 2024-03-31 | $0.01B  | 17.23%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE       |
|------------|---------|-----------|
| 2025-03-31 | $0.93B  | -21.68%   |
| 2024-12-31 | $1.03B  | -17.29%   |
| 2024-09-30 | $0.52B  | -18.27%   |
| 2024-06-30 | $0.58B  | -16.69%   |
| 2024-03-31 | $0.40B  | -22.78%   |

**Analysis:**
*   **Revenue and Profitability:** Revenue has been relatively low and inconsistent, with some quarters showing higher revenue than others. The profit margins are highly variable, with significant losses in some quarters and positive margins in others. This variability suggests that the company's profitability is unstable and dependent on specific events or contracts.
*   **Capital and Profitability:** The company's equity has fluctuated, indicating changes in the company's capital structure. The negative Return on Equity (ROE) values indicate that the company is not generating profits relative to its equity, which is a concern for investors.

### 7. Overall Summary

RXRX has significantly underperformed the S&P 500 and exhibits high volatility. While recent price action suggests a short-term upward trend, the company's fundamentals remain weak with consistent losses and negative expected returns. Recent news indicates ongoing events and uncertainty.  The combination of high risk, negative profitability, and substantial underperformance warrants extreme caution. The strong recent price movement could be a short-term reaction to news rather than a sustainable trend.

**In Conclusion:** Based on the provided data, an investment in RXRX appears highly speculative and carries significant risk. More in-depth research and a thorough understanding of the company's pipeline and financial strategy are essential before considering an investment.
